RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Korn, D., Thieme, A. J., Alves, V. M., Yeakey, M., Borba, J. V. V. B., Capuzzi, S. J., Fecho, K., Bizon, C., Edwards, S. W., Chirkova, R., Colvis, C. M., Southall, N. T., Austin, C. P., Muratov, E. N., & Tropsha, A. (2022). Defining clinical outcome pathways. Drug Discovery Today, 27(6), 1671-1678. https://doi.org/10.1016/j.drudis.2022.02.008
Here, we propose a broad concept of 'Clinical Outcome Pathways' (COPs), which are defined as a series of key molecular and cellular events that underlie therapeutic effects of drug molecules. We formalize COPs as a chain of the following events: molecular initiating event (MIE) → intermediate event(s) → clinical outcome. We illustrate the concept with COP examples both for primary and alternative (i.e., drug repurposing) therapeutic applications. We also describe the elucidation of COPs for several drugs of interest using the publicly accessible Reasoning Over Biomedical Objects linked in Knowledge-Oriented Pathways (ROBOKOP) biomedical knowledge graph-mining tool. We propose that broader use of COP uncovered with the help of biomedical knowledge graph mining will likely accelerate drug discovery and repurposing efforts.